RxDoctor Payments Data

Alexander Trujillo, MD

Interventional Cardiology · Tomball, TXNPI 1255595609

Payments from drug & device makers

$14,323in general payments, 2019–2025

Across 426 payments — averaging $33.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$7K
  • Boston Scientific$801
  • Johnson & Johnson$601
  • AstraZeneca$588
  • Abbott$583
  • Merck$559
  • plus $5K from 37 others

What the payments were for

  • Travel & lodging$5,45138%
  • Food & beverage$8,74161%
  • Education$1301%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,323 in reported general payments places this provider in the 55th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$717,606
Medicare patients
338
Services billed
3,342

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban355$385,573
EliquisApixaban345$360,346
EntrestoSacubitril/Valsartan170$206,962
JardianceEmpagliflozin72$112,465
FarxigaDapagliflozin Propanediol86$93,700
BrilintaTicagrelor135$89,045
VerquvoVericiguat67$77,484
VascepaIcosapent Ethyl34$21,453
Ezetimibe613$19,484
Repatha SureclickEvolocumab16$10,654
Rosuvastatin Calcium535$10,623
Ranolazine ErRanolazine20$3,821
Atorvastatin Calcium346$3,245
Nitroglycerin230$2,286
Olmesartan Medoxomil30$2,084

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$601$385,573355 claims
PfizerEliquis$245$360,346345 claims
NovartisEntresto$457$206,962170 claims
AstraZenecaFarxiga, Brilinta$588$182,745221 claims
Boehringer IngelheimJardiance$409$112,46572 claims
MerckVerquvo$559$77,48467 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Tomball

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →